Leadership & Pay ·
TransCode Therapeutics announced that Thomas A. Fitzgerald resigned as Chief Financial Officer and director effective…
RNAZTranscode Therapeutics, Inc.
TransCode Therapeutics announced that Thomas A. Fitzgerald resigned as Chief Financial Officer and director effective September 9, 2026, due to no disagreement with the company. His resignation triggers a Separation Agreement providing up to $1,250,000 in severance, contingent on funding thresholds of $5 million or $10 million within one year. All outstanding equity awards vested immediately, and he received a new option for 185,000 shares with performance-based acceleration. John Tattory was appointed Interim CFO effective the same date. TransCode Therapeutics operates in the biotechnology industry, focusing on developing RNA-based therapeutics.